The primary focus within this research theme will be to develop drugs for which pharmaceutical industry has less interest, either because they are for a rare disease (or otherwise small patient population) or because of patent expiration. The national ZonMW program Future Affordable and Sustainable Therapies (FAST) perfectly matches the Leiden initiative.
The LUMC, Leiden University, Centre for Human Drug Research (CHDR) and Leiden Bio Science Park (LBSP) together have the expertise and facilities for the design, development and testing of new innovative drugs. This environment is unique in the Netherlands, and provides an excellent basis for drug discovery and drug development.
The Leiden Bio Science Park (LBSP) encompasses more than a hundred international biomedical companies, including many start-ups. Innovation and valorization, alongside research and education in Academic Pharma, will strengthen the ties with companies in the LBSP.
For more information contact mailto: firstname.lastname@example.org
PEP-TALK Teun van Gelder: How do you make medicines?
The development of a new therapeutic drug is a complex, lengthy and expensive process: the initial concept, its testing, effectiveness and finally the hospital market can take 10-15 years or longer.
Professor Teun van Gelder, clinical pharmacologist at the LUMC, is giving a ten minute explanation about how Academic Pharma plays an increasingly important role in this process.